COVID-19 Disease Clinical Trial
Official title:
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection
A Phase II Randomized, double-blind, Placebo-controlled Study to Evaluate the safety and efficacy of exosomes overexpressing CD24 to prevent clinical deterioration .The study population will include patients with moderate or severe COVID-19 infection and laboratory markers predictive of the cytokine storm from the Corona department of each site, who have provided an informed consent. 155 patients will be randomized in a 2:1 ratio to receive either 1010 exosome particles (103 patients) or placebo (52 patients).The exosomes will be diluted in 4ml normal saline for inhalation, administered once daily (QD) for 5 days. Placebo (saline) will be prepared for inhalation and administered in the same manner as the exosomes.
The exosomes will be diluted in 4ml normal saline for inhalation, administered once daily (QD) for 5 days. Placebo (saline) will be prepared for inhalation and administered in the same manner as the exosomes. Study treatments will be given as add-on to standard of care. Following the 5 days of treatment, patients will remain in follow-up for 23 additional days. Patients who will be discharged before the end of the 5-day treatment period will continue to receive treatment at home. Treatment administration and the study assessments will be carried out by the research personnel at the home of the patient, implementing the required protective measures. On Day 28, when the isolation period is completed, these patients will arrive at the study site for the follow-up visit. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04984408 -
Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
|
Phase 3 | |
| Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04587323 -
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
|
||
| Completed |
NCT04682873 -
A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus
|
Phase 3 | |
| Completed |
NCT04359212 -
Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
|
||
| Completed |
NCT05603130 -
Epidemiologic Register on Diabetes and COVID-19 in Tunisia
|
||
| Completed |
NCT04830800 -
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC
|
Phase 1/Phase 2 | |
| Completed |
NCT04757792 -
Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
|
||
| Active, not recruiting |
NCT04417257 -
Study of LAU-7b for the Treatment of COVID-19 Disease in Adults
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04522037 -
Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
|
||
| Completed |
NCT04446377 -
A Study of LAM-002A for the Prevention of Progression of COVID-19
|
Phase 2 | |
| Completed |
NCT04366024 -
A Novel Nomogram to Predict Severity of COVID-19
|
||
| Completed |
NCT04347369 -
A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease
|
||
| Completed |
NCT04787510 -
COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
|
||
| Completed |
NCT05329220 -
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
|
Phase 3 | |
| Active, not recruiting |
NCT05077267 -
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
|
Phase 2 | |
| Completed |
NCT04472013 -
Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19
|
||
| Active, not recruiting |
NCT04371354 -
Outcomes of Covid-19 Protective Measures in Endoscopy
|
||
| Not yet recruiting |
NCT04779359 -
Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease
|